NASDAQ:TBPH Theravance Biopharma (TBPH) Stock Price, News & Analysis $8.01 -0.16 (-1.96%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$8.01▼$8.2050-Day Range$7.66▼$10.2552-Week Range$7.44▼$11.71Volume190,620 shsAverage Volume241,105 shsMarket Capitalization$391.85 millionP/E RatioN/ADividend YieldN/APrice Target$13.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Theravance Biopharma alerts: Email Address Theravance Biopharma MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside71.7% Upside$13.75 Price TargetShort InterestBearish12.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 2 Articles This WeekInsider TradingAcquiring Shares$7.80 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.04) to $0.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector688th out of 910 stocksPharmaceutical Preparations Industry320th out of 426 stocks 3.2 Analyst's Opinion Consensus RatingTheravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageTheravance Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Theravance Biopharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.38% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently increased by 2.01%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TBPH. Previous Next 1.9 News and Social Media Coverage News SentimentTheravance Biopharma has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Theravance Biopharma this week, compared to 2 articles on an average week.Search Interest5 people have searched for TBPH on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Theravance Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have bought 21,562.33% more of their company's stock than they have sold. Specifically, they have bought $7,798,440.00 in company stock and sold $36,000.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Theravance Biopharma is held by insiders.Percentage Held by Institutions99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Theravance Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Theravance Biopharma are expected to grow in the coming year, from ($1.04) to $0.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheravance Biopharma has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Theravance Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressEXPOSED: Hotspot Dates for popular stocks Did you know almost every stock in the market has multiple “Hotspot Dates”? They indicate when the stock has gone up on the same dates… at the same time… FOR DECADES For example, have you ever traded a stock called Constellation Energy (ticker: CEG)? Maybe not… Energy stocks haven’t received much love over the past 12 months. But anybody who knew about the “Hotspot Date” during the last week in January…Go here to get Roger’s top FIVE Hotspot Stocks for This Month! About Theravance Biopharma Stock (NASDAQ:TBPH)Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Read More TBPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TBPH Stock News HeadlinesAugust 10, 2024 | insidertrades.comEli Samaha Buys 999,800 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) StockSeptember 6 at 7:46 PM | finance.yahoo.comHere's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn SituationSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.September 3, 2024 | americanbankingnews.comBrokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $13.75August 30, 2024 | americanbankingnews.comTheravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q3 2024 Earnings of ($0.23) Per Share, Zacks Research ForecastsAugust 28, 2024 | americanbankingnews.comQ4 2025 EPS Estimates for Theravance Biopharma, Inc. Increased by Analyst (NASDAQ:TBPH)August 27, 2024 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceAugust 15, 2024 | finance.yahoo.comSeth Klarman's Strategic Reduction in Theravance Biopharma IncSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 10, 2024 | finance.yahoo.comNeed To Know: Analysts Just Made A Substantial Cut To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) EstimatesAugust 8, 2024 | msn.comSmall Cap Stocks: TBPH Stock Isn’t Ideal for Short Term InvestorsAugust 6, 2024 | markets.businessinsider.comTheravance Biopharma: Hold Rating Maintained Amid Adjusted Sales Expectations and Development DelaysAugust 6, 2024 | msn.comLeerink Partners Downgrades Theravance Biopharma (TBPH)August 6, 2024 | seekingalpha.comTheravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | marketwatch.comTheravance Biopharma Shares Dip to 52-Week Low After Wider-Than-Expected 2Q LossAugust 6, 2024 | markets.businessinsider.comHold Rating on Theravance Biopharma Amidst Revised Revenue Projections and Pipeline DelaysAugust 6, 2024 | benzinga.comCracking The Code: Understanding Analyst Reviews For Theravance BiopharmaAugust 6, 2024 | msn.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call TranscriptSee More Headlines Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees359Year FoundedN/APrice Target and Rating Average Stock Price Target$13.75 High Stock Price Target$21.00 Low Stock Price Target$9.00 Potential Upside/Downside+71.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,190,000.00 Net Margins-73.61% Pretax Margin-61.63% Return on Equity-21.29% Return on Assets-11.94% Debt Debt-to-Equity RatioN/A Current Ratio5.20 Quick Ratio5.20 Sales & Book Value Annual Sales$57.42 million Price / Sales6.82 Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book2.02Miscellaneous Outstanding Shares48,920,000Free Float45,277,000Market Cap$391.85 million OptionableOptionable Beta0.24 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesRick E. WinninghamChairman & Chief Executive OfficerAndrew Asa HindmanChief Financial Officer & Senior Vice PresidentVijay SabesanSenior Vice President-Technical OperationsPhilip D. WorboysSenior VP-Research & Translational ScienceBradford J. ShaferSecretary, Executive VP & General CounselKey CompetitorsAnnexonNASDAQ:ANNXPliant TherapeuticsNASDAQ:PLRXKura OncologyNASDAQ:KURASchrödingerNASDAQ:SDGRArcus BiosciencesNYSE:RCUSView All CompetitorsInsiders & InstitutionsThe Manufacturers Life Insurance Company Sold 2,431 shares on 8/15/2024Ownership: 0.034%Point72 Asia Singapore Pte. Ltd.Sold 2,749 shares on 8/15/2024Ownership: 0.019%Marshall Wace LLPBought 135,426 shares on 8/14/2024Ownership: 0.608%Bank of Montreal CanBought 93,702 shares on 8/14/2024Ownership: 0.327%Squarepoint Ops LLCBought 116,256 shares on 8/14/2024Ownership: 0.238%View All Insider TransactionsView All Institutional Transactions TBPH Stock Analysis - Frequently Asked Questions How have TBPH shares performed this year? Theravance Biopharma's stock was trading at $11.24 at the beginning of 2024. Since then, TBPH stock has decreased by 28.7% and is now trading at $8.01. View the best growth stocks for 2024 here. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) issued its quarterly earnings data on Monday, August, 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.25. The biopharmaceutical company had revenue of $14.26 million for the quarter, compared to analysts' expectations of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative trailing twelve-month return on equity of 21.29%. Who are Theravance Biopharma's major shareholders? Theravance Biopharma's top institutional shareholders include Baupost Group LLC MA (8.59%), Dimensional Fund Advisors LP (0.68%), Marshall Wace LLP (0.61%) and SG Americas Securities LLC (0.33%). Insiders that own company stock include Richard A Graham and Rhonda Farnum. View institutional ownership trends. How do I buy shares of Theravance Biopharma? Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ) and Merck & Co., Inc. (MRK). This page (NASDAQ:TBPH) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
